Hormone therapy (ADT), using luteinizing hormone releasing hormone (LHRH) agonists or gonadatropin releasing hormone or GnRH agonists (Lupron, Zoladex, Trelstar, Viadur, Vantas, Eligard and Synarel ) have been known to have many side effects, some severe and potentially life threatening. Many of us believe that ADT is associated with cardiovascular disease and diabetes along with a myriad other morbidity issues. During the last few years the relationship of ADT and these potentially life threatening diseases has become become a bigger question.
The Food & Drug Administration (FDA) has announced that it will be evaluating the role these drugs have in increasing the risk for diabetes and cardiovascular disease. The FDA safety announcement (05-03-2010), “FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certain cardiovascular diseases” states that (GnRH) Agonists may increase the risk of diabetes and certain cardiovascular diseases (heart attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer.
The safety announcement asserts that in six published reports the use of ADT appears to cause a slight increase r